NCT00727961View on ClinicalTrials.gov

A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED)

PHASE4CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

November 9, 2004

Primary Completion Date

January 10, 2008

Study Completion Date

January 10, 2008

Conditions
Ovarian Neoplasms
Interventions
DRUG

Pegylated Liposomal Doxorubicin hydrochloride

Caelyx Intravenous, 50 mg/m\^2 (60 minute infusion) on day 1, every 4 weeks, during 6 cycles

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00727961 - A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED) | Biotech Hunter | Biotech Hunter